Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1. The inhibitors are compounds of the general formula: ##STR00001##

2-Benzylidene hydrazinoadenosine compounds having A.sub.2A adenosine receptor agonistic activity, represented by a general Formula (I) and pharmaceutical compositions containing the same. The compounds and compositions can act as A.sub.2A adenosine receptor agonist to serve as medicaments.

##STR00001##

2-Benzylidene hydrazinoadenosine compounds having A.sub.2A adenosine receptor agonistic activity, represented by a general Formula (I) and pharmaceutical compositions containing the same. The compounds and compositions can act as A.sub.2A adenosine receptor agonist to serve as medicaments.

##STR00001##

Nucleoside or nucleotide analog compounds having the structure shown below, a method for preparing them, and applications in nucleic acid sequencing are disclosed. The compounds have formula (I): ##STR00001## wherein L.sub.1, L.sub.2, and L.sub.3 are each independently a covalent bond or a covalently linked group; B is a base or a base derivative selected from purines, pyrimidines, or analogs thereof; R.sub.1 is —OH, a phosphate group, or a nucleotide; R.sub.2 as H or a cleavable group; R.sub.3 is a detectable group or a targeting group; R.sub.5 is an inhibitory group; R.sub.4 is H, —NH.sub.2, or —OR.sub.6, wherein R.sub.6 is H or a cleavable group; and C is a cleavable group or a cleavable bond.

Nucleoside or nucleotide analog compounds having the structure shown below, a method for preparing them, and applications in nucleic acid sequencing are disclosed. The compounds have formula (I): ##STR00001## wherein L.sub.1, L.sub.2, and L.sub.3 are each independently a covalent bond or a covalently linked group; B is a base or a base derivative selected from purines, pyrimidines, or analogs thereof; R.sub.1 is —OH, a phosphate group, or a nucleotide; R.sub.2 as H or a cleavable group; R.sub.3 is a detectable group or a targeting group; R.sub.5 is an inhibitory group; R.sub.4 is H, —NH.sub.2, or —OR.sub.6, wherein R.sub.6 is H or a cleavable group; and C is a cleavable group or a cleavable bond.

Disclosed are a 5′-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5′-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5′-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.

##STR00001##

Embodiments of the present disclosure provide compositions comprising compounds useful to make radiotracers for positron emission tomography imaging, as well as methods for making and using these compositions.

Embodiments of the present disclosure provide compositions comprising compounds useful to make radiotracers for positron emission tomography imaging, as well as methods for making and using these compositions.

The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties.

The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties.